β‐Lactam regimens for the febrile neutropenic patient

Gerald P. Bodey, Victor Fainstein, Linda S. Elting, Elias Anaissie, Kenneth Rolston, Nancy Khardori, Hagop Kantarjian, Carl Plager, William K. Murphy, Frankie Holmes, Fernando Cabanillas

Research output: Contribution to journalArticle

44 Scopus citations

Abstract

A total of 535 evaluable febrile episodes in neutropenic patients were randomly assigned to treatment with ticarcillin-clavulanate plus vancomycin (TV), ceftazidime plus vancomycin (CV), or all three antibiotics (TCV). The TCV regimen was significantly more effective than TV, considering all evaluable episodes, documented infections, gram-negative infections, and infections in patients with persistent severe neutropenia (< 100 neutrophils/mm3). The results with CV were intermediate between TV and TCV. The toxicities were similar with all three regimens and consisted primarily of skin rashes. The TCV regimen is effective for empiric therapy of fever in neutropenic patients and probably should be utilized in preference to CV or TV, although its superiority over CV in this study was inconclusive.

Original languageEnglish (US)
Pages (from-to)9-16
Number of pages8
JournalCancer
Volume65
Issue number1
DOIs
StatePublished - Jan 1 1990

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'β‐Lactam regimens for the febrile neutropenic patient'. Together they form a unique fingerprint.

Cite this